Neogabin 75 capsules 75 mg No. 10

Neogabin capsules are prescribed for the following indications:

Composition

Active ingredient: pregabalin;

1 capsule contains 75 mg of pregabalin;

Excipients: microcrystalline cellulose, croscarmellose sodium, magnesium stearate, talc hard gelatin capsule: gelatin, titanium dioxide (E 171).

Contraindication

Hypersensitivity to the active substance or to any of the excipients of the drug.

Method of application

The drug is prescribed in a dose of 150 to 600 mg/day, divided into 2 or 3 doses. The drug can be used regardless of meals. This drug is intended for oral use only.

Application features

Pregnant women

Should not be used during pregnancy unless necessary.

Drivers

It is recommended to refrain from driving.

Overdose

After the drug was marketed, the most common adverse reactions reported in pregabalin overdose were drowsiness, confusion, agitation, and restlessness. Seizures have also been reported.

Rare cases of coma have been reported.

Treatment of pregabalin overdose consists of general supportive measures and may include hemodialysis if necessary.

Side effects

The most commonly reported adverse reactions were dizziness and somnolence. Adverse reactions were usually mild to moderate in severity. In all controlled trials, the rate of discontinuation due to adverse reactions was 12% in patients receiving pregabalin and 5% in patients receiving placebo. The most common adverse reactions leading to discontinuation of study drug in the pregabalin group were dizziness and somnolence.

Interaction

Pregabalin may potentiate the effects of ethanol and lorazepam. In controlled clinical trials, multiple oral doses of pregabalin with oxycodone, lorazepam, or ethanol did not result in clinically significant effects on respiratory function. During post-marketing surveillance, cases of respiratory failure, coma, and death have been reported in patients taking pregabalin with other CNS depressants, particularly in patients abusing such substances. Pregabalin is likely to potentiate the cognitive and gross motor impairments caused by oxycodone.

Storage conditions

Store out of the reach of children, in the original packaging at a temperature not exceeding 25 °C.

Shelf life - 2 years.